Dr. Ling is Professor of Psychiatry and Director of Integrated Substance Abuse Programs (ISAP) at UCLA, one of the foremost substance abuse research groups in the US and worldwide. He is board certified in neurology and psychiatry, is active in research and clinical work, and has been listed in “Best Doctors in America”, “Best Doctors in the West” and “Best Doctors in Los Angeles”.
Dr. Ling’s research in opiate pharmacotherapy provided pivotal information for the approval of LAAM, naltrexone and buprenorphine. His current research includes prescription opiate abuse and dependence, opiate induced hyperalgesia, treatment of pain in opiate-maintained patients, including those treated with buprenorphine, and the role of buprenorphine in the management of pain in these patients. The research scope of the Integrated Substance Abuse Programs (ISAP) has encompassed the development of medications and psychosocial strategies for the treatment of opiate, cocaine, methamphetamine, alcohol and nicotine abuse and dependence. As Principal Investigator of NIDA’s Clinical Trial Network’s Pacific Region Node, Doctor Ling has extended ISAP’s research beyond the US to Asia and the Middle East.